# Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

> **NCT02263508** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 713 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Talimogene Laherparepvec
- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02263508
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-08
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-03-11
- **Target enrollment:** 713 (ACTUAL)
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02263508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02263508, "Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02263508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*